220 related articles for article (PubMed ID: 21130036)
1. Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction.
Pierzynski P
Reprod Biomed Online; 2011 Jan; 22(1):9-16. PubMed ID: 21130036
[TBL] [Abstract][Full Text] [Related]
2. Atosiban improves implantation and pregnancy rates in patients with repeated implantation failure.
Lan VT; Khang VN; Nhu GH; Tuong HM
Reprod Biomed Online; 2012 Sep; 25(3):254-60. PubMed ID: 22818095
[TBL] [Abstract][Full Text] [Related]
3. Oxytocin antagonists may improve infertility treatment.
Pierzynski P; Reinheimer TM; Kuczynski W
Fertil Steril; 2007 Jul; 88(1):213.e19-22. PubMed ID: 17481622
[TBL] [Abstract][Full Text] [Related]
4. Barusiban suppresses oxytocin-induced preterm labour in non-human primates.
Reinheimer TM
BMC Pregnancy Childbirth; 2007 Jun; 7 Suppl 1(Suppl 1):S15. PubMed ID: 17570159
[TBL] [Abstract][Full Text] [Related]
5. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
6. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
Chan WY; Wo NC; Cheng LL; Manning M
J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
[TBL] [Abstract][Full Text] [Related]
7. Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF.
Moraloglu O; Tonguc E; Var T; Zeyrek T; Batioglu S
Reprod Biomed Online; 2010 Sep; 21(3):338-43. PubMed ID: 20638340
[TBL] [Abstract][Full Text] [Related]
8. A randomized double blind comparison of atosiban in patients undergoing IVF treatment.
Ng EH; Li RH; Chen L; Lan VT; Tuong HM; Quan S
Hum Reprod; 2014 Dec; 29(12):2687-94. PubMed ID: 25336707
[TBL] [Abstract][Full Text] [Related]
9. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
10. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus.
Nilsson L; Reinheimer T; Steinwall M; Akerlund M
BJOG; 2003 Nov; 110(11):1025-8. PubMed ID: 14592588
[TBL] [Abstract][Full Text] [Related]
11. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin and oxytocin in normal reproduction and in the pathophysiology of preterm labour and primary dysmenorrhoea. Development of receptor antagonists for therapeutic use in these conditions.
Akerlund M
Rocz Akad Med Bialymst; 2004; 49():18-21. PubMed ID: 15631309
[TBL] [Abstract][Full Text] [Related]
13. Use of an oxytocin antagonist in in vitro fertilization-embryo transfer for women with repeated implantation failure: a retrospective study.
Chou PY; Wu MH; Pan HA; Hung KH; Chang FM
Taiwan J Obstet Gynecol; 2011 Jun; 50(2):136-40. PubMed ID: 21791296
[TBL] [Abstract][Full Text] [Related]
14. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea.
Akerlund M; Melin P; Maggi M
Adv Exp Med Biol; 1995; 395():595-600. PubMed ID: 8714023
[TBL] [Abstract][Full Text] [Related]
15. Oxytocin antagonists for the management of preterm birth: a review.
Usta IM; Khalil A; Nassar AH
Am J Perinatol; 2011 Jun; 28(6):449-60. PubMed ID: 21170825
[TBL] [Abstract][Full Text] [Related]
16. The combination tocolytic effect of magnesium sulfate and an oxytocin receptor antagonist in myometrium from singleton and twin pregnancies.
Arrowsmith S; Neilson J; Wray S
Am J Obstet Gynecol; 2016 Dec; 215(6):789.e1-789.e9. PubMed ID: 27555315
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
[TBL] [Abstract][Full Text] [Related]
18. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.
Serradeil-Le Gal C; Valette G; Foulon L; Germain G; Advenier C; Naline E; Bardou M; Martinolle JP; Pouzet B; Raufaste D; Garcia C; Double-Cazanave E; Pauly M; Pascal M; Barbier A; Scatton B; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 2004 Apr; 309(1):414-24. PubMed ID: 14722330
[TBL] [Abstract][Full Text] [Related]
19. Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy.
Richter ON; Dorn C; van de Vondel P; Ulrich U; Schmolling J
Arch Gynecol Obstet; 2005 Jun; 272(1):26-30. PubMed ID: 15909190
[TBL] [Abstract][Full Text] [Related]
20. Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin.
Stam WB; Van der Graaf PH; Saxena PR
Br J Pharmacol; 1998 Oct; 125(4):865-73. PubMed ID: 9831926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
